Drug Enforcement Administration
US controlled-substance regulator; registration, security, and recordkeeping obligations that run alongside cGMP for any site handling scheduled drugs.
WHAT DEA COVERS
The Drug Enforcement Administration is a US Department of Justice agency that regulates controlled substances under the Controlled Substances Act, with its requirements codified in 21 CFR parts 1300–1321. Any person who manufactures, distributes, dispenses, imports, exports, or conducts research with a controlled substance must register with DEA, and registration is granted per activity and per location rather than per company. Its remit is diversion — keeping controlled substances inside the legitimate supply chain — not product quality.
WHERE IT SITS INTERNATIONALLY
The Controlled Substances Act implements US obligations under the UN Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971), with the International Narcotics Control Board administering the international estimates and quota system. DEA is not an ICH or PIC/S participant — it sits outside the GMP harmonisation architecture entirely. Its interface with the medicines system is scheduling, where DEA acts on the scientific and medical evaluation provided by HHS and FDA, and registration, which a manufacturer holds separately from any FDA establishment registration.
HOW ITS REQUIREMENTS BITE
DEA enforces through registration. A registration is a privilege that can be denied, suspended, or revoked, and the agency's Diversion Investigators conduct scheduled regulatory investigations of registrants against Part 1301 security and Part 1304 recordkeeping requirements. Escalation runs through administrative action — an Order to Show Cause, or an Immediate Suspension Order where there is imminent danger — to civil penalties and criminal prosecution. Losing a DEA registration stops controlled-substance operations at that site regardless of how strong its GMP record is.
WHAT DEA PUBLISHES
- 0121 CFR parts 1300–1321 — the binding regulations covering registration, security, recordkeeping, order forms, quotas, and disposal
- 02Aggregate production quotas and individual quota determinations for Schedule I and II substances
- 03Federal Register scheduling actions — placements, rescheduling, and temporary scheduling orders
- 04The Pharmacist's Manual and Practitioner's Manual — DEA's operational interpretation for each registrant category
- 05Published administrative decisions on registration actions, which are the practical enforcement record
WHAT PRACTITIONERS GET WRONG
- ›DEA compliance runs parallel to GMP, not inside it — a site can be fully cGMP-compliant and still be shut down over a Part 1301 security or Part 1304 recordkeeping failure.
- ›Reconciliation is the core discipline: the biennial inventory, perpetual records for Schedule I and II substances, and reporting theft or significant loss on DEA Form 106.
- ›Physical security is specified in construction terms in §1301.72 — vault and cage requirements are far cheaper to design in than to retrofit.
- ›Quotas under Part 1303 cap how much controlled API a manufacturer may procure or produce, which makes DEA a supply-planning constraint and not only a compliance one.
- ›For distributors, suspicious order monitoring under §1301.74(b) is an enforced obligation and belongs to compliance, not to commercial teams.
DEA STANDARDS SPEQ DECODES · 2
DISCIPLINES IN DEA’S REMIT
Track DEA — and every regulator that matters
New rules, guidance, enforcement, and inspection signals from Drug Enforcement Administration and its peers worldwide, distilled into the free Weekly GxP Briefing.